Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

NCT03432741 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

17

Enrollment

OTHER

Sponsor class

Stopped funding - sponsor filing Chapter 11 bankruptcy

Conditions

Breast Adenocarcinoma
Metastatic Breast Carcinoma
Recurrent Breast Carcinoma
Recurrent Hodgkin Lymphoma
Recurrent Mycosis Fungoides
Recurrent Non-Hodgkin Lymphoma
Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Refractory Breast Carcinoma
Refractory Hodgkin Lymphoma
Refractory Mycosis Fungoides
Refractory Nodal Marginal Zone Lymphoma
Refractory Non-Hodgkin Lymphoma
Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Stage IV Breast Cancer AJCC v6 and v7

Interventions

DRUG: Belinostat
DRUG: Carfilzomib
DRUG: Copanlisib Hydrochloride
BIOLOGICAL: Daratumumab
DRUG: Fludeoxyglucose F-18
DRUG: Gemcitabine Hydrochloride
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Nivolumab
BIOLOGICAL: Obinutuzumab
BIOLOGICAL: Pembrolizumab
PROCEDURE: Positron Emission Tomography
BIOLOGICAL: Rituximab
DRUG: Romidepsin
OTHER: Saline
BIOLOGICAL: Trastuzumab

Sponsor

Mayo Clinic